麻豆传媒

I am Professor and Chair of the Department of Molecular and Cellular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina, Charleston, South Carolina. I am also the John C. West Chair in Cancer Research and Director of the Developmental Cancer Therapeutics Program at the Hollings Cancer Center.
I received a B.Sc. in microbiology/genetics from the University of Wales, Swansea, UK; a PhD in biochemical pharmacology; and a DSc. from the University of London. My past research and teaching positions include Georgetown University School of Medicine, Lombardi Cancer Center, Fox Chase Cancer Center, and the University of Pennsylvania.
I have served on numerous peer review committees and scientific advisory boards in the United States, Canada, Italy, UK, and United Arab Emirates.
I am currently serving as chair of ASPET’s Publication Committee. I previously served as editor in chief for the Journal of Pharmacology and Experimental Therapeutics and associate editor for Molecular Pharmacology, as well as held several other roles with editorial boards of many other journals.
 
My primary research interests include anticancer drug discovery/development and drug target identification, mechanisms of redox stress response, glutathione metabolism, and mechanisms of drug resistance. I have published over 170 research articles; 130 editorials, reviews, and book chapters; and two books. Additionally, I served as an editor on nearly 20 books and hold a number of patents.
 

Dr. Joel Mason is Senior Scientist and Leader of the Vitamins and Carcinogenesis Team at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. He studies the cellular pathways by which 1-carbon nutrients, obesity, and the colonic microbiome alter the risk of cancer formation, and his team develops strategies based on this knowledge for the purposes of cancer prevention. Among Dr. Mason’s research accomplishments is the elaboration of cellular mechanisms by which abundant intake of folate protects against colon cancer, insights into how folate availability interacts with certain genetic traits and environmental factors in determining the risk of developing breast and colon cancer, and the demonstration—in both animal models and humans—that obesity incites inflammation and precancerous molecular changes in the lining of the colon. Dr. Mason has authored some of the most frequently cited papers in his field. He has been ranked as a Top Doctor in the U.S. (top 1% of all physicians) and top Cancer Doctor in the U.S. by Castle Connolly Limited, and is consistently rated by his peers as one of the top gastroenterologists in Boston, MA (Boston Magazine) and the U.S. as a whole (U.S. 麻豆传媒 & World Report). He is currently researching the combinations of pharmacologic, dietary, and microbiologic agents in the prevention of obesity-induced colon cancer. Dr. Mason is also a Professor of Medicine at Tufts University School of Medicine and Professor of Nutrition at the Friedman School of Nutrition Science and Policy, and is an Associate Editor of the American Journal of Clinical Nutrition. He is a staff physician in the Divisions of Clinical Nutrition and Gastroenterology at Tufts Medical Center. Dr. Mason is a fellow of the American Gastroenterological Association and a member of the American Association for Cancer Research and American Society for Nutrition.

Dr. Rong Fan is the Harold Hodgkinson Professor of Biomedical Engineering and of Pathology. His research interest has been centered on the development and deployment of single-cell and spatial omics technologies to investigate normal development, aging, and disease. He received a B.S. in Applied Chemistry from University of Science and Technology of China, a Ph.D. in Chemistry from the University of California at Berkeley, and then completed his postdoctoral training at California Institute of Technology, prior to joining the faculty of Department of Biomedical Engineering at Yale University in 2010. He developed a microchip that allows for simultaneous measurement of 42 immune effector proteins in single cells at high throughput, which remains the highest multiplexing to date for a single-cell protein secretion assay. In collaboration with Novartis and Kite Pharma, it was applied to profiling antigen-specific activation states of chimeric antigen receptor (CAR)-engineered T cells, resulting in the discovery of novel single-cell biomarkers including polyfunctional strength index to characterize the quality of CAR-T infusion products and predict the clinical responses and immune-related adverse effects(irAEs) prior to treatment. This microchip, called IsoCode, and the automation system, called IsoLight, have been commercialized by IsoPlexis, a company co-founded by Dr. Fan. Now, this system has been used by >100 major pharmaceutical companies and cancer centers around the world for monitoring CAR-T or checkpoint inhibitor immunotherapies. Dr. Fan is also a pioneer in developing NGS-based spatial omics sequencing technologies. He conceived the concept of spatial multi-omics and developed the first spatially resolved multi-omics sequencing technology called DBiT-seq (Liu et al., Cell 183, 1665–1681, 2020) which allows for spatial co-profiling of whole transcriptome and hundreds of proteins (spatial-CITE-seq) at cellular level in complex tissues. He further developed a first-of-its-kind technology to enable spatial epigenome sequencing including spatial-ATAC-seq (Deng et al., Nature 609 (7926), 375-383, 2022) and spatial-CUT&Tag (Deng et al., Science 375 (6581), 681-686, 2022). These technologies may unlock a whole new field in spatial biology with applications in a wide range of biological and biomedical research. Dr. Fan co-founded IsoPlexis, Singleron Biotechnologies, and AtlasXomics. He is the recipient of multiple awards including the NCI Howard Temin Career Transition Award, the NSF CAREER Award, and the Packard Fellowship for Science and Engineering. He has been elected to American Institute for Medical and Biological Engineering (AIMBE), Connecticut Academy of Science and Engineering (CASE), and the National Academy of Inventors (NAI).